Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Hartmut Döhner, Courtney D. DiNardo, Frederick Appelbaum, et al.
Blood (2024) Vol. 144, Iss. 21, pp. 2169-2173
Closed Access | Times Cited: 20

Showing 20 citing articles:

Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies
Jayastu Senapati, Sanam Loghavi, Jennifer Marvin‐Peek, et al.
American Journal of Hematology (2025)
Closed Access | Times Cited: 1
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 1
Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia
Fenghong Zhang, Yizi Liu, Yiyan Zhu, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-11
Closed Access
Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
Giovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, et al.
American Journal of Hematology (2025)
Open Access
Biology and Management of Acute Myeloid Leukemia With Mutated NPM1
Evan C. Chen, Shai Shimony, Marlise R. Luskin, et al.
American Journal of Hematology (2025)
Closed Access
Sharpening the Tools to Get the Edge on Leukemia
Shai Shimony, Jacqueline S. Garcia
American Journal of Hematology (2025)
Open Access
Metabolism and therapeutic response in acute myeloid leukemia with IDH1/2 mutations
Ludovic Gabellier, Enzo Bosetta, Maël Heiblig, et al.
Trends in cancer (2025)
Closed Access
The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry
Ιωάννα Λαζανά, Maria Papathanassiou, Ioannis Konstantellos, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 667-667
Open Access
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents
Tom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
Leukemia (2025)
Open Access
TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
Mithun Vinod Shah, Daniel A. Arber, Devendra Hiwase
American Journal of Hematology (2025)
Open Access
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation
Jayastu Senapati, Hagop M. Kantarjian, Fadi G. Haddad, et al.
American Journal of Hematology (2024) Vol. 100, Iss. 2, pp. 249-259
Closed Access | Times Cited: 3
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Pasquale Niscola, Valentina Gianfelici, Gianfranco Catalano, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6632-6658
Open Access | Times Cited: 1
A simplified risk model for pretreatment stratification of newly diagnosed acute myeloid leukemia patients treated with venetoclax and azacitidine
N Islam, Jamie S. Reuben, Justin Dale, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Venetoclax and Azacitidine Combination is an Effective Salvage Regimen for Fit Patients with IDH-2-mutated Acute Myeloid Leukemia Refractory to Conventional Induction Chemotherapy
Musa Alzahrani
Journal of Applied Hematology (2024) Vol. 15, Iss. 4, pp. 326-330
Open Access | Times Cited: 1
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Maximilian Fleischmann, Madlen Jentzsch, Annamaria Brioli, et al.
Annals of Hematology (2024)
Open Access
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment
Shan Zheng, Yuxin Tong, Linlin Yang, et al.
Annals of Hematology (2024)
Closed Access
The Aza/Ven reshuffle
Mark J. Levis
Blood (2024) Vol. 144, Iss. 21, pp. 2159-2160
Closed Access
Effektiver und vielfältiger: Optionen für die nicht intensive Krankheitskontrolle bei unfitten AML-Patienten
Lutz Kretschmer, Veit Bücklein, Marion Subklewe, et al.
Trillium Krebsmedizin (2024) Vol. 33, Iss. 6, pp. 406-411
Closed Access
Comparable Short Term Outcomes Among Patients with Newly Diagnosed Acute Myeloid Leukemia with or without Myelodysplasia Related Gene Mutations Treated with Azacytidine-Venetoclax: Observations from a Single Center Retrospective Cohort
Rudra Narayan Swain, Sarthak Wadhera, Charanpreet Singh, et al.
Indian Journal of Hematology and Blood Transfusion (2024)
Closed Access
Somatic co‐alteration signatures are prognostic in high‐grade TP53‐mutated myeloid neoplasms
Emily Symes, Peng Wang, Payal Sojitra, et al.
British Journal of Haematology (2024)
Open Access
Page 1

Scroll to top